We are live on ! Find out more
RPAM

Rhenman & Partners Asset Management Portfolio holdings

AUM $810M
1-Year Est. Return 30.2%
This Fund
S&P 500
This Quarter Est. Return
+6.58%
1 Year Est. Return
+30.2%
3 Year Est. Return
+116.38%
5 Year Est. Return
+153.13%
10 Year Est. Return
+962.25%
AUM
$333M
AUM Growth
+$77.5M
Cap. Flow
+$78M
Cap. Flow %
23.42%
Top 10 Hldgs %
35.62%
Holding
104
New
20
Increased
33
Reduced
37
Closed
13

Top Buys

Rank Stock Value
1
PFE icon
Pfizer
PFE
+$11.1M
2
GILD icon
Gilead Sciences
GILD
+$11M
3
ALXN
Alexion Pharmaceuticals
ALXN
+$9.82M
4
MDVN
MEDIVATION, INC.
MDVN
+$7.71M
5
REGN icon
Regeneron Pharmaceuticals
REGN
+$5.79M

Top Sells

Rank Stock Value
1
INVA icon
Innoviva
INVA
+$4.71M
2
ARIA
Ariad Pharmaceuticals Inc
ARIA
+$3.6M
3
ISRG icon
Intuitive Surgical
ISRG
+$3.07M
4
ZBH icon
Zimmer Biomet
ZBH
+$2.8M
5
AET
Aetna Inc
AET
+$2.74M

Sector Composition

Rank Sector Weight
1 Healthcare 79.75%
2 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AET
101
DELISTED
Aetna Inc
AET
– –
-40,000
Closed -$2.74M
NVDQ
102
DELISTED
Novadaq Technologies Inc.
NVDQ
– –
-25,000
Closed -$412K
BCR
103
DELISTED
CR Bard Inc.
BCR
– –
-13,000
Closed -$1.74M
1 2 3 4
5

Similar funds

PS
Portfolio Strategies Monsey, New York $811M AUM 28.91% 1-Year Est. Return
ACM
Ashford Capital Management Wilmington, Delaware $809M AUM 35.1% 1-Year Est. Return
AR
Advisory Research Chicago, Illinois $813M AUM 36.71% 1-Year Est. Return
KCP
Kera Capital Partners San Jose, California $815M AUM 46.39% 1-Year Est. Return
BCM
Brigade Capital Management New York $806M AUM 20.71% 1-Year Est. Return
RIM
Redwood Investment Management Scottsdale, Arizona $805M AUM 15.01% 1-Year Est. Return
GCM
Glendon Capital Management Santa Monica, California $805M AUM 17.91% 1-Year Est. Return
CL
CVFG LLC Shelbyville, Indiana $804M AUM 27.61% 1-Year Est. Return

Rhenman & Partners Asset Management's Q1 2014 Portfolio in Review

As of Q1 2014, Rhenman & Partners Asset Management held 104 positions worth $333M, up 30% from $256M the previous quarter. Its ten largest holdings account for 36% of the portfolio.

Rhenman & Partners Asset Management deployed $78M of net new capital in Q1 2014, opening 20 new positions and adding to 33 existing holdings. Its largest new stake was Pfizer: 372,050 shares worth $11.3M.

By sector, the portfolio is most concentrated in Healthcare at 80% of assets, down from 83% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Ariad Pharmaceuticals Inc, an estimated $3.6M trimmed.

  • Rhenman & Partners Asset Management's largest Q1 2014 buy was Pfizer: 372,050 shares worth $11.3M.
  • Rhenman & Partners Asset Management added most to Gilead Sciences in Q1 2014, an estimated $11M increase.
  • Rhenman & Partners Asset Management's biggest Q1 2014 reduction was Ariad Pharmaceuticals Inc, cutting an estimated $3.6M.
  • Rhenman & Partners Asset Management fully exited Innoviva in Q1 2014, selling an estimated $4.71M.
  • Rhenman & Partners Asset Management's ten largest holdings make up 36% of its $333M portfolio in Q1 2014.
  • Rhenman & Partners Asset Management opened 20 new positions and closed 13 in Q1 2014.
  • Rhenman & Partners Asset Management's portfolio value rose 30% quarter-over-quarter to $333M.

Based on Rhenman & Partners Asset Management's 13F filing for Q1 2014, filed 14 May 2014.